Yongfang Qin1, Qian Xu1, Tingwei Xu2, Hai Yuan1, Fengqi Hu1. 1. Department of Nephrology, Xiangyang Central Hospital, Hubei University of Arts and Science Hubei, China. 2. Department of Neurosurgery, Xiangyang Central Hospital, Hubei University of Arts and Science Hubei, China.
Abstract
OBJECTIVE: To analyze clinical characteristics and prognostic factors of patients with malignancies combined with acute kidney injury (AKI), providing a basis for clinical AKI prevention and prognosis improvement. METHOD: Hospitalized patients in the Central Hospital of Nephrology from January 2008 to December 2013 were screened by electronic medical record system; Statistical analysis formalignant tumor patients associated with AKI was conducted. The clinical features of these patients in 6 years were analyzed and compared, and Logistic regression analysis was used to analyze the risk factors of hospitalized mortality in patients with and malignant tumor and AKI. RESULTS: There were 340 cases of malignancies associated with AKI patients, accounting for 30.0% (340/1133) of AKI patients in the same period. In malignancy patients, hematological malignancies accounted for 12.9% (44/340); non-metastatic solid tumor accounted for 54.7% (186/340); metastatic solid tumor accounted for 32.4% (110/340). In factors leading to AKI, post-renal obstruction [60% (204/340)], nephrotoxic drugs or contrast agents [27.9% (95/340)] and hypovolemia [41/340 (12.1%)] were common in patients with malignant tumors. There was no significant difference in the cause of AKI between early 3 years and later 3 years (P>0.05). Hospital mortality in patients with malignancies associated with AKI was [22.9% (78/340)], with an annually declining trend. Multivariate Logistic regression showed that: multiple etiologies, multiple organ failure, metastatic solid tumor, sepsis, and continuous renal replacement therapy were independent risk factors for hospital mortality. CONCLUSION: AKI is a common complication in patients with malignant tumors, with post-renal obstruction as the most common factors. Hospital mortality in malignant tumor patients associated with AKI was higher, and the prevention of AKI is crucial in clinical.
OBJECTIVE: To analyze clinical characteristics and prognostic factors of patients with malignancies combined with acute kidney injury (AKI), providing a basis for clinical AKI prevention and prognosis improvement. METHOD: Hospitalized patients in the Central Hospital of Nephrology from January 2008 to December 2013 were screened by electronic medical record system; Statistical analysis formalignant tumor patients associated with AKI was conducted. The clinical features of these patients in 6 years were analyzed and compared, and Logistic regression analysis was used to analyze the risk factors of hospitalized mortality in patients with and malignant tumor and AKI. RESULTS: There were 340 cases of malignancies associated with AKI patients, accounting for 30.0% (340/1133) of AKI patients in the same period. In malignancypatients, hematological malignancies accounted for 12.9% (44/340); non-metastatic solid tumor accounted for 54.7% (186/340); metastatic solid tumor accounted for 32.4% (110/340). In factors leading to AKI, post-renal obstruction [60% (204/340)], nephrotoxic drugs or contrast agents [27.9% (95/340)] and hypovolemia [41/340 (12.1%)] were common in patients with malignant tumors. There was no significant difference in the cause of AKI between early 3 years and later 3 years (P>0.05). Hospital mortality in patients with malignancies associated with AKI was [22.9% (78/340)], with an annually declining trend. Multivariate Logistic regression showed that: multiple etiologies, multiple organ failure, metastatic solid tumor, sepsis, and continuous renal replacement therapy were independent risk factors for hospital mortality. CONCLUSION: AKI is a common complication in patients with malignant tumors, with post-renal obstruction as the most common factors. Hospital mortality in malignant tumorpatients associated with AKI was higher, and the prevention of AKI is crucial in clinical.
Authors: Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: Amit Lahoti; Hagop Kantarjian; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William Wierda; Gloria N Mattiuzzi Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Márcio Soares; Jorge I F Salluh; Marilia S Carvalho; Michael Darmon; José R Rocco; Nelson Spector Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Dominique D Benoit; Eric A Hoste; Pieter O Depuydt; Fritz C Offner; Norbert H Lameire; Koenraad H Vandewoude; Annemieke W Dhondt; Lucien A Noens; Johan M Decruyenaere Journal: Nephrol Dial Transplant Date: 2005-01-25 Impact factor: 5.992